X

Trial Profile

Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacokinetics

Most Recent Events

01 Aug 2022 Results assessing the relationship between treatment efficacy and exposure of total and unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations, published in the Cancer Chemotherapy and Pharmacology.
09 May 2016 Status changed from recruiting to active, no longer recruiting.
15 Apr 2015 Planned number of patients changed from 50 to 70 as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com